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ABSTRACT
Background: Recently, especially in Japan, several researchers have suggested that colorectal cancer can develop
not only through an adenoma-carcinoma sequence but also from normal mucosa via a de novo pathway, and that
these de novo cancers have more aggressive malignant potential. We report a case of aggressive colon cancer
resulting in systemic metastasis despite small tumour size.
Case Presentation: A 35-year-old woman presented at the referring hospital with swelling of the left cervical
lymph node. Biopsy of the lymph node revealed metastatic adenocarcinoma; however, CT scan and
mammography were unable to identify the site of the primary lesion. She was diagnosed with unknown primary
cancer and referred to our hospital for further examination. Immunohistochemical reevaluation showed the cervical
lymph node biopsy specimen to be positive for CDX2 and CK20 and negative for CK7 expression, leading us to
suspect the presence of a primary colorectal cancer. We performed a total colonoscopy, and detected a small
protruding lesion in the transverse colon. The tumour was only 12 mm in diameter, with a central depressed
component and a severely thickened stalk, which suggested direct cancer invasion of the deep submucosa. We
concluded that this lesion was the site of origin of the metastasis despite the small tumour size, and performed
diagnostic endoscopic mucosal resection. The lesion was found to have an intramucosal cancer component,
demonstrating that this lesion represented primary colon cancer. The patient was referred to the gastrointestinal
oncology division for systemic chemotherapy.
Conclusions: In this case, immunohistochemical findings strongly suggested the existence of a colorectal cancer.
The non-polypoid gross appearance of the tumour suggested that it can originate de novo , thus providing a
valuable case in support of the aggressive malignant potential of a de novo colorectal cancer pathway.
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Background
Colorectal cancer is the second leading cause of cancer
deaths in men and women in Western countries [1], and
its incidence is gradually increasing in Japan as well. The
most common pathway of colorectal cancer development
is thought to be the adenoma-carcinoma sequence, in
which carcinoma develops from an adenomatous polyp
[2]. The current practice of removing adenomatous
polyps of the colon and rectum is based on the belief that
this will prevent colorectal cancer [3]. However, recent
reports have described small depressed [4], leading to the
proposal of an alternative pathway of de novo colon carci-
nogenesis, which involves an aggressive growth pheno-
type and quick infiltration of neighbouring tissue and
lymph nodes [5-7]. The most common site of metastasis
of these cancers is the liver, followed by the lung. Herein,
w er e p o r tar a r ec a s eo fas m a l lc o l o nc a n c e rw i t ha
depressed component and aggressive malignant potential
with systemic metastasis, where the chief complaint was
cervical lymph node swelling.
Case Presentation
In September 2009, a 35-year-old woman presented at
the referring hospital with left cervical lymph node
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but aspiration cytology and biopsy of the lymph node
suggested metastatic adenocarcinoma resulting from
breast cancer. However, no evidence of breast cancer
was found on ultrasonography and mammography
examinations. Whole-body computed tomography (CT)
showed systemic lymph node swellings (left supraclavi-
cular and multiple para-aortic lymph nodes) but no pri-
mary lesion (Figure 1). Upper Gastrointestinal
endoscopy revealed no evidence of malignancy. The
patient was diagnosed with unknown primary cancer
and referred to our hospital for further examination in
November 2009.
We reevaluated the lymph node biopsy specimen
obtained by the referring hospital. The tumour cells
with oval to round nuclei with prominent nucleoli were
found to be showing partial ductal structures, leading us
to suspect poorly differentiated adenocarcinoma. Addi-
tionally, immunohistochemistry (IHC) studies showed
t h eb i o p s ys p e c i m e nt ob en e g a t i v ef o rc y t o k e r a t i n7
(CK7), and positive for CDX2, an intestine-specific
homeobox transcription factor, and cytokeratin 20
(CK20), a cytoskeletal protein usually found in the colo-
nic epithelium. These IHC results strongly suggested the
metastasis from a primary colorectal cancer (Figure 2).
We performed a total colonoscopy and detected a small
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Figure 1 Whole-body computed tomography (CT) findings. Systemic lymph node swelling was observed. (A) Left supraclavicular lymph
node metastasis measuring 33 mm in diameter (arrowhead). (B) Middle thoracic para-oesophageal lymph node metastasis measuring 24 mm in
diameter (arrowhead). (C) Multiple para-aortic lymph node metastases in the abdomen, the largest one measuring 43 mm in diameter
(arrowhead). (D) Left iliac internal lymph node metastasis measuring 18 mm.
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Figure 2 Pathological findings of lymph node metastasis. (A, B) Poorly differentiated adenocarcinoma was observed, with tumour cells
spreading into fibrosis stroma in the tumour tissue. Tumour cells contained acidophilic vacuoles and oval nuclear bodies with several clear
nucleoluses and partially formed glandular differentiations. (C) Immunohistochemical staining for CK20 was positive. (D) Immunohistochemical
staining for CK7 was negative. (E) Immunohistochemical staining for CDX2 was weak but diffusely positive.
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Figure 3 Colonoscopy findings. (A) Conventional colonoscopy showed a protruding lesion with central depression in the transverse colon,
12 mm in diameter. Its stalk was severely thickened, suggesting cancer invasion. (B) Chromoendoscopy with 0.4% indigo-carmine dye clearly
showed the depressed area and non-neoplastic mucosa covering the edge of the cancer, suggesting that this tumour followed a non-polypoid
growth (NPG)-type pattern. (C, D) Magnified NBI (Narrow Band Imaging) micrograph of the central depressed area, showing loose, irregular
capillary vessels. We diagnosed the tumour as type IIIB according to Sano’s classification, which suggests the possibility of deep cancer invasion
of the submucosal layer. (E) Magnified view with 0.05% crystal violet staining of the surface of the central depression with a severe irregular pit
pattern identified in the demarcated area.
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tumour was very small, with a diameter of only about
12 mm, and contained a depressed component, leading
to a diagnosis of macroscopic type with 0-Is+IIc accord-
ing to the Paris classification [8]. Furthermore, the
severely thickened stalk and irregular pits visible in a
magnified image of the depressed area combined to sug-
gest direct invasion of the deep submucosa (Figure 3C)
[9]. We concluded that this lesion was the primary site
of the metastatic cancer despite its small size.
A diagnostic endoscopic mucosal resection (EMR)
was performed and the specimen removed was serially
dissected into three sections and examined. The
tumour was composed of poorly differentiated adeno-
carcinoma and signet-ring cell carcinoma (Figure 4). It
primarily consisted of solidly proliferated cells, but
exhibited some indistinct gland formation. The tumour
had a preserved intramucosal component but infil-
trated deeply into the submucosal layer, with severe
lymphatic and venous invasion detected the submuco-
sal layer. The vertical and horizontal cut ends of the
resected tumour were both positive for cancer cells
(Figure 4). IHC studies showed strong expression of
MUC5AC, and weak expression of MUC2 and CDX2;
indicating the tumour having a mixed gastric and
intestinal character, with the gastric phenotype being
predominant. Patients with advanced colorectal cancer
with gastric phenotypes have been reported to fre-
quently exhibit lymphatic permeation and lymph node
metastasis [10]. Additionally, the tumour was positive
for CK20 and slightly positive for CK7. There was no
evidence of differentiation to endocrine tumour or
hepatoid adenocarcinoma (Figure 5).
These pathological results suggested that colon cancer
was the origin of lymph node metastasis. The patient
was referred to the Gastrointestinal Oncology Division,
where she underwent combination chemotherapy using
capecitabine (Xeloda
® ) plus oxaliplatin (Elplat
® )a n d
bevacizumab (Avastin
® ), which is one of the standard
therapy of metastatic colon cancer. After 4 courses, CT
scan showed a significant reduction of tumour volume,
but after 10 courses, the tumour marker rapidly
increased and peritoneal metastasis progressed. The
genomic analysis of KRAS status revealed wild type, so
we started the second-line combination chemotherapy
using cetuximab (Erbitax
® ) plus irinotecan hydrochlor-
ide (Topotecin
® ). After the 4 times administration of
cetuximab, tumor marker was decreased significantly.
Her age, i.e. 35-years, is in accordance with the Guide-
line, which are used as recommendation criteria for MSI
testing. However, she did not agree to undergo MSI
testing, because she would like to give top priority to
receive the chemotherapy.
Conclusions
In patients with an unknown primary carcinoma, the
site remains unidentified in 15~25% of the cases even
after autopsy [11,12], although recent advances in clini-
cal examination and diagnostic work-up have decreased
this frequency. The median survival of high-risk patients
with cancer of unknown primary origin ranges from 3
to 11 months, making prompt diagnosis and treatment
very important [13-15]. In this case, 2 months elapsed
between the initial consultation at the referring institu-
tion and the patient’s presentation at our hospital.
Pathological and IHC reviews of cervical lymph node
tissue were the main tools used to determine the pri-
mary site of cancer origin.
When attempting to trace the primary site of a meta-
static tumour of unknown origin, clarification of the his-
tological type is indispensable in selecting appropriate
treatment. Microscopic features and cell morphologies
can be identified with hematoxylin and eosin (HE) stain-
ing, and this information can be used to identify the pri-
mary site. However, in the evaluation of undifferentiated
or poorly differentiated cancers, IHC evaluation is a use-
ful addition to HE staining in locating the tumour site.
In particular, a pattern of positive CDX2 or CK20
expression and negative CK7 expression is indicative of
primary colorectal cancer [16,17].
In this case, IHC investigation of a lymph node biopsy
strongly suggested primary colorectal cancer. In a total
colonoscopy examination, we detected one colorectal
lesion with the gross appearance of a submucosal
tumour. This appearance is relatively rare in primary
colon cancer, and thus we should exclude metastatic
colon cancer as a possible diagnosis. EMR is more use-
ful than simple biopsy in confirming the existence of a
mucosal component, which would lead to a primary
cancer diagnosis, but it carries a high risk of bleeding
and perforation in cases where deep submucosal inva-
sion is suspected. We performed diagnostic EMR after
obtaining proper consent and agreement.
The adenoma-carcinoma sequence hypothesis pro-
poses that colorectal cancers arise from adenomatous
polyps. Alternately, several researchers, especially in
Japan, have suggested that colorectal cancer can also
d e v e l o pf r o mn o r m a lm u c o s a ,i nade novo process
involving morphological changes from a small superfi-
cial-type carcinoma to depressed-type carcinoma. De
novo cancers are thought to have an aggressive growth
phenotype, despite small tumour size, and to quickly
infiltrate neighbouring tissue and lymph nodes. In this
case, the tumour exhibited a severely thickened stalk,
which suggested direct cancer invasion of the deep sub-
mucosa, and a clearly demarcated depressed area in the
centre of the lesion, suggesting that it can originate de
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Figure 4 Pathological results of endoscopic mucosal resection. (A) An intramucosal component corresponding to the depressed lesion was
observed. The tumour formed a massive invasion below the muscularis propria. (B-1,2) The tumour was composed of poorly differentiated
adenocarcinoma and signet-ring cell carcinoma, mostly formed by solidly proliferating cells but with some indistinct gland formation. (C) The
tumour had an intramucosal component, but infiltrated deeply into the submucosal layer with severe lymphatic and venous invasion. (D)
Extensive lymphatic and venous invasion was detected mainly under the muscularis propria.
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viour. This case of small primary colon cancer with sys-
temic metastasis provides valuable support for the
aggressive malignant potential of the de novo pathway in
colorectal carcinogenesis.
In conclusion, we have reported a rare case of small
primary colon cancer with systemic metastasis
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Figure 5 Immunohistochemical investigation of the resected specimen. (A) Weak CDX-2 expression was observed in the carcinoma. (B)
MUC-2 expression was observed. (C) MUC5AC expression was observed. (D) MUC6 expression was not observed.
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